Literature DB >> 6983268

Accelerated skeletal deterioration after splenectomy in Gaucher type 1 disease.

J S Rose, G A Grabowski, S H Barnett, R J Desnick.   

Abstract

Entities:  

Mesh：

Year:  1982        PMID： 6983268     DOI： 10.2214/ajr.139.6.1202

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN： 0361-803X            Impact factor:   3.959


× No keyword cloud information.
  9 in total

1.  Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy.

Authors:  G Ciana; R Addobbati; G Tamaro; A Leopaldi; M Nevyjel; L Ronfani; L Vidoni; M G Pittis; B Bembi
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 2.  Clinically relevant therapeutic endpoints in type I Gaucher disease.

Authors:  C E Hollak; M Maas; J M Aerts
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

3.  Laparoscopic fenestration for a huge symptomatic splenic cyst in a patient with Gaucher's disease.

Authors:  Kyohei Abe; Hiroaki Shiba; Junichi Shimada; Shinji Onda; Taro Sakamoto; Katsuhiko Yanaga
Journal:  Clin J Gastroenterol       Date:  2018-03-23

4.  Splenectomy in patients with undiagnosed splenomegaly.

Authors:  C C Cronin; M P Brady; C Murphy; E Kenny; M J Whelton; C Hardiman
Journal:  Postgrad Med J       Date:  1994-04       Impact factor: 2.401

5.  Severe skeletal complications in Japanese patients with type 1 Gaucher disease.

Authors:  H Ida; O M Rennert; S Kato; T Ueda; K Oishi; K Maekawa; Y Eto
Journal:  J Inherit Metab Dis       Date:  1999-02       Impact factor: 4.982

6.  Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.

Authors:  G A Grabowski; T Dinur; K M Osiecki; J R Kruse; G Legler; S Gatt
Journal:  Am J Hum Genet       Date:  1985-05       Impact factor: 11.025

Review 7.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

8.  Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.

Authors:  Pramod K Mistry; Julie L Batista; Hans C Andersson; Manisha Balwani; Thomas Andrew Burrow; Joel Charrow; Paige Kaplan; Aneal Khan; Priya S Kishnani; Edwin H Kolodny; Barry Rosenbloom; C Ronald Scott; Neal Weinreb
Journal:  Am J Hematol       Date:  2017-07-07       Impact factor: 10.047

9.  The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.

Authors:  Patrick Deegan; Aneal Khan; José Simon Camelo; Julie L Batista; Neal Weinreb
Journal:  Orphanet J Rare Dis       Date:  2021-02-18       Impact factor: 4.123
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.